Jefferies Defends Epizyme (EPZM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
FDA AdCom Positive on Epizyme (EPZM) Tazemetostat
December 18, 2019 11:48 AM ESTFDA AdCom positive on Epizyme (NASDAQ: EPZM) Tazemetostat. 11 Yes votes that the benefits outweigh the risks. 0 No votes. (shares halted)
... MorePre-Open Movers 12/16: (AXSM) (INFN) (BMRN) Higher (WVE) (PCG) (BA) Lower (more...)
December 16, 2019 9:23 AM ESTToday's Pre-Open Movers
Axsome Therapeutics, Inc. (NASDAQ: AXSM) 78.5% HIGHER; announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary endpoint and rapidly and significantly improved symptoms of depression in the GEMINI Phase 3 trial in major depressive disorder (MDD). The GEMINI study was a randomized, double-blind, placebo-controlled, multi-center, U.S. trial, in which 327 adult patients with confirmed moderate to severe MDD were randomized to treatment with either AXS-05 (dextromethorphan/bupropion modulated delivery tablet) or placebo once daily for the first 3 days and twice... More
Epizyme (EPZM) on watch with FDA briefing documents released
December 16, 2019 8:24 AM ESTEpizyme (NASDAQ: EPZM) on watch with FDA briefing documents released (LINK)
... More